5-year survival seen for over 40% of ALS patients on masitinib in trial
WHY IT MATTERS
If masitinib gains approval, ALS patients may have access to a treatment that could significantly extend their survival time compared to current standard care.
A new drug called masitinib helped ALS patients live longer than expected. In a clinical trial, over 40% of patients treated with masitinib survived for at least 5 years from when their disease started. This is much better than the typical outcome, where fewer than 25% of ALS patients usually live that long.
Nearly half of the people with amyotrophic lateral sclerosis (ALS) treated with masitinib in a clinical trial survived for at least five years from disease onset — a marked improvement over historical data showing fewer than 1 in 4 ALS patients typically live this long — indicating what the therapy’s developer called “substantial survival benefits.” […] The post 5-year survival seen for over 40% of ALS patients on masitinib in trial appeared first on ALS News Today .
ASK YOUR DOCTOR
Talk to your neurologist about whether you might be eligible for masitinib trials or ask about the latest updates on this drug's development timeline.